Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009-2010.

Cui X, Nolen LD, Sun J, Booth M, Donaldson L, Quinn CP, Boyer AE, Hendricks K, Shadomy S, Bothma P, Judd O, McConnell P, Bower WA, Eichacker PQ.

Emerg Infect Dis. 2017 Jan;23(1):56-65. doi: 10.3201/eid2301.160608.

2.

Ileocecal resection for massive rectal bleeding due to Yersinia enterocolitica: a case report and review of the literature.

Azghari I, Bargach A, Billah NM, Essaoudi MA, Jahid A, Kabbaj N.

J Med Case Rep. 2016 Jan 19;10:6. doi: 10.1186/s13256-015-0786-2. Review.

3.

Does Bacillus anthracis Lethal Toxin Directly Depress Myocardial Function? A Review of Clinical Cases and Preclinical Studies.

Suffredini DA, Sampath-Kumar H, Li Y, Ohanjanian L, Remy KE, Cui X, Eichacker PQ.

Toxins (Basel). 2015 Dec 12;7(12):5417-34. doi: 10.3390/toxins7124891. Review.

4.

Antimicrobial Treatment for Systemic Anthrax: Analysis of Cases from 1945 to 2014 Identified Through a Systematic Literature Review.

Pillai SK, Huang E, Guarnizo JT, Hoyle JD, Katharios-Lanwermeyer S, Turski TK, Bower WA, Hendricks KA, Meaney-Delman D.

Health Secur. 2015 Nov-Dec;13(6):355-64. doi: 10.1089/hs.2015.0033. Epub 2015 Dec 1. Review.

5.

An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Ohanjanian L, Remy KE, Li Y, Cui X, Eichacker PQ.

Expert Opin Investig Drugs. 2015;24(7):851-65. doi: 10.1517/13543784.2015.1041587. Epub 2015 Apr 28. Review.

6.

Pediatric anthrax clinical management.

Bradley JS, Peacock G, Krug SE, Bower WA, Cohn AC, Meaney-Delman D, Pavia AT; AAP Committee on Infectious Diseases and Disaster Preparedness Advisory Council.

Pediatrics. 2014 May;133(5):e1411-36. doi: 10.1542/peds.2014-0563.

7.

Therapeutic plasma exchange as rescue therapy in severe sepsis and septic shock: retrospective observational single-centre study of 23 patients.

Hadem J, Hafer C, Schneider AS, Wiesner O, Beutel G, Fuehner T, Welte T, Hoeper MM, Kielstein JT.

BMC Anesthesiol. 2014 Apr 7;14:24. doi: 10.1186/1471-2253-14-24.

8.

The sepsis model: an emerging hypothesis for the lethality of inhalation anthrax.

Coggeshall KM, Lupu F, Ballard J, Metcalf JP, James JA, Farris D, Kurosawa S.

J Cell Mol Med. 2013 Jul;17(7):914-20. doi: 10.1111/jcmm.12075. Epub 2013 Jun 7.

9.

Bacillus anthracis cell wall peptidoglycan but not lethal or edema toxins produces changes consistent with disseminated intravascular coagulation in a rat model.

Qiu P, Li Y, Shiloach J, Cui X, Sun J, Trinh L, Kubler-Kielb J, Vinogradov E, Mani H, Al-Hamad M, Fitz Y, Eichacker PQ.

J Infect Dis. 2013 Sep;208(6):978-89. doi: 10.1093/infdis/jit247. Epub 2013 Jun 3.

10.

Cellular and physiological effects of anthrax exotoxin and its relevance to disease.

Lowe DE, Glomski IJ.

Front Cell Infect Microbiol. 2012 Jun 1;2:76. doi: 10.3389/fcimb.2012.00076. eCollection 2012. Review.

11.

An overview of anthrax infection including the recently identified form of disease in injection drug users.

Hicks CW, Sweeney DA, Cui X, Li Y, Eichacker PQ.

Intensive Care Med. 2012 Jul;38(7):1092-104. doi: 10.1007/s00134-012-2541-0. Epub 2012 Apr 24. Review.

12.

Allelic variation on murine chromosome 11 modifies host inflammatory responses and resistance to Bacillus anthracis.

Terra JK, France B, Cote CK, Jenkins A, Bozue JA, Welkos SL, Bhargava R, Ho CL, Mehrabian M, Pan C, Lusis AJ, Davis RC, LeVine SM, Bradley KA.

PLoS Pathog. 2011 Dec;7(12):e1002469. doi: 10.1371/journal.ppat.1002469. Epub 2011 Dec 29.

13.

Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines.

Barochia AV, Cui X, Sun J, Li Y, Solomon SB, Migone TS, Subramanian GM, Bolmer SD, Eichacker PQ.

J Infect Dis. 2012 Mar 1;205(5):818-29. doi: 10.1093/infdis/jir834. Epub 2012 Jan 5.

14.

Anthrax infection.

Sweeney DA, Hicks CW, Cui X, Li Y, Eichacker PQ.

Am J Respir Crit Care Med. 2011 Dec 15;184(12):1333-41. doi: 10.1164/rccm.201102-0209CI. Epub 2011 Aug 18. Review.

15.

Delayed treatment with W1-mAb, a chimpanzee-derived monoclonal antibody against protective antigen, reduces mortality from challenges with anthrax edema or lethal toxin in rats and with anthrax spores in mice.

Altaweel L, Chen Z, Moayeri M, Cui X, Li Y, Su J, Fitz Y, Johnson S, Leppla SH, Purcell R, Eichacker PQ.

Crit Care Med. 2011 Jun;39(6):1439-47. doi: 10.1097/CCM.0b013e3182120691.

Supplemental Content

Support Center